Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain

Clinical and Translational Oncology

Volumn 12, Issue 10, 2010, Pages 692-700

  Frías, Carmen ^a   Cortés, Javier ^b   Seguí, Miguel Ángel ^a   Oyagüez, Itziar ^c   Casado, Miguel Ángel ^c  

^a Hospital Universitari Parc Taulí   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

Cost effectiveness; Docetaxel; Metastatic breast cancer; Paclitaxel

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; ERYTHROPOIETIN; ERYTHROPOIETIN ALPHA; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; RANITIDINE; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; HEALTH CARE COST; HUMAN; INFECTION; METASTASIS POTENTIAL; MOTOR NEURON DISEASE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; PAIN; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SENSORY DYSFUNCTION; SKIN DISEASE; SPAIN; STOMATITIS; TREATMENT DURATION; VOMITING;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MARKOV CHAINS; PACLITAXEL; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; SPAIN; TAXOIDS;

EID: 78649639749     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0579-4     Document Type: Article

References (46)

1. Ministerio de Sanidad y Consumo (2005) La situación del cáncer en España. Available at http://www.msc.es/ciudadanos/ enfLesiones/enf-NoTransmisibles/docs/situacionCancer.pdf
2. A. Izquierdo R. Gispert F. Saladie J.A. Espinàs 2008 Análisis de la incidencia, la supervivencia y la mortalidad segÚn las principales localizaciones tumorales, 1985-2019: cáncer de mama Med Clin (Barc) 131 Suppl1 50 52 10.1016/S0025-7753(08)76433-9
3. M. Martín E. Mahillo A. Llombart-Cussac, et al. 2006 The "El Alamo" project (1990-1997): two consecutive hospital-based studies of breast cancer outcomes in Spain Clin Transl Oncol 8 508 518 10.1007/s12094-006- 0051-7 16870541
4. E. Remák L. Brazil 2004 Cost of managing women presenting with stage IV breast cancer in the United Kingdom Br J Cancer 91 77 83 10.1038/sj.bjc.6601890 15188011 (Pubitemid 39013048)
5. Grupo Español para el Desarrollo de la Farmacia Oncológica 2008 Estudio transversal del tratamiento del cáncer de mama en España Farm Hosp 32 139 147 10.1016/S1130-6343(08)72832-0
6. P. Conte B. Salvadori S. Donati, et al. 2001 Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer Semin Oncol 28 2Suppl.7 15 17 1:CAS:528:DC%2BD3MXksVyhsbw%3D 10.1016/S0093-7754(01)90273-8 11372047 (Pubitemid 32476740)
7. J. O'shaughnessy 2005 Extending survival with chemotherapy in metastatic breast cancer Oncologist 10 Suppl3 20 29 10.1634/theoncologist.10-90003-20 16368868 (Pubitemid 43152727)
8. L.G. Estevez I. Tusquets M. Muñoz, et al. 2007 Advanced breast cancer: chemotherapy phase III trials that change a standard Anticancer Drugs 18 843 859 1:CAS:528:DC%2BD2sXms12isbs%3D 10.1097/CAD.0b013e3280bad81a 17581310 (Pubitemid 46975974)
9. M.J. Higgins A.C. Wolff 2008 Therapeutic options in the management of metastatic breast cancer Oncology (Williston Park) 22 614 623
10. D. Ghersi N. Wilcken J. Simes E. Donoghue 2005 Taxane containing regimens for metastatic breast cancer Cochrane Database Syst Rev Apr 18 2 CD003366
11. K.A. Lyseng-Williamson C. Fenton 2005 Docetaxel: a review of its use in metastatic breast cancer Drugs 65 2513 2531 1:CAS:528:DC%2BD28XnvVyntg%3D%3D 10.2165/00003495-200565170-00007 16296875 (Pubitemid 41697318)
12. D.P. Figgitt L.R. Wiseman 2000 Docetaxel. An update of its use in advanced breast cancer Drugs 59 621 651 1:CAS:528:DC%2BD3cXjtV2htrY%3D 10.2165/00003495-200059030-00015 10776837
13. R.E. Brown J. Hutton A. Burrell 2001 Cost-effectiveness of treatment options in advanced breast cancer in the UK Pharmacoeconomics 19 1091 1102 1:STN:280:DC%2BD3Mnpt1yitA%3D%3D 10.2165/00019053-200119110-00003 11735676
14. E.A. Perez C.L. Vogel D.H. Irwin, et al. 2001 Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer J Clin Oncol 19 4216 4223 1:CAS:528:DC%2BD38XhslWqtA%3D%3D 11709565
15. A. Eniu F.M. Palmieri E.A. Perez 2005 Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer Oncologist 10 665 685 1:CAS:528:DC%2BD2MXht1Cgs7fK 10.1634/theoncologist.10-9-665 16249346 (Pubitemid 41567278)
16. J.A. Sparano M. Wang S. Martino, et al. 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663 1671 1:CAS:528:DC%2BD1cXkslCitLk%3D 10.1056/NEJMoa0707056 18420499 (Pubitemid 351549913)
17. S.E. Jones 2008 Metastatic breast cancer: the treatment challenge Clin Breast Cancer 8 224 233 1:CAS:528:DC%2BD1cXovFCiu7s%3D 10.3816/CBC.2008.n.025 18650152 (Pubitemid 351962143)
18. E. Saloustros D. Mavroudis V. Georgoulias 2008 Paclitaxel and docetaxel in the treatment of breast cancer Expert Opin Pharmacother 9 2603 2616 1:CAS:528:DC%2BD1cXhtFegtL7F 10.1517/14656566.9.15.2603 18803448
19. N. Wilcken R. Dear 2008 Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007 Eur J Cancer 44 2218 2225 1:CAS:528:DC%2BD1cXht1Sis7rM 10.1016/j.ejca.2008.07.019 18722111
20. S.E. Jones J. Erban B. Overmoyer, et al. 2005 Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer J Clin Oncol 23 5542 5551 1:CAS:528:DC%2BD2MXhtVersr%2FN 10.1200/JCO.2005.02.027 16110015
21. Jones SE, Benedict A, Cameron D, Jourdan S (2007) Cost-effectiveness of docetaxel compared to paclitaxel in metastatic breast cancer: A UK health economic analysis. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25, 18S (June 20 Supplement):1081
22. T. Vu S. Ellard C.H. Speers, et al. 2008 Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation Ann Oncol 19 461 464 1:STN:280:DC%2BD1c7ksVajsQ%3D%3D 10.1093/annonc/mdm527 18006892 (Pubitemid 351325665)
23. Z. Lwin N. Leighl 2009 Economic evaluation of docetaxel for breast cancer Expert Opin Pharmacother 10 283 290 1:CAS:528:DC%2BD1MXntlOlsA%3D%3D 10.1517/14656560802653206 19236199
24. A. Benedict D.A. Cameron H. Corson S.E. Jones 2009 An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK Pharmacoeconomics 27 847 59 10.2165/10899510-000000000-00000 19803539
25. Lee E, Wang JW (2003) Statistical methods for survival data analysis, 3rd edn. Wiley Interscience, Indianapolis
26. Verrill MW, Lee J, Cameron DA for the Anglo-Celtic IV trial (2007) First results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly Paclitaxel in patients with locally advanced or metastatic breast cancer (ABC) J Clin Oncol. ASCO Annual Meeting Proceedings Part I. 25:LBA1005
27. o 2006/22. Available at http://aunets.isciii.es/ficherosproductos/132/MemoriaFinal.pdf
28. A.H. Briggs A.M. Gray 1999 Handling uncertainty when performing economic evaluation of healthcare interventions Health Technol Assess 3 1 134 1:STN:280:DyaK1MzotVOlsg%3D%3D 10448202
29. A. Lloyd B. Nafees J. Narewska 2006 Health state utilities for metastatic breast cancer Br J Cancer 95 683 690 1:STN:280:DC%2BD28rktVGhsQ%3D%3D 10.1038/sj.bjc.6603326 16967055 (Pubitemid 44373482)
30. IMS Health. MIDAS, MAT. Dec 2009 [database]
31. Oblikue Consulting (2009). Base de datos sanitarios e-Salud Available at http://www.oblikue.com/bddcostes/.
32. Consejo General de Colegios de Farmacéuticos 2009 Catálogo de Medicamentos. Consejo Plus. Madrid. Available at http://www.portalfarma.com
33. A. Briggs M. Sculpher 1998 An introduction to Markov modelling for economic evaluation Pharmacoeconomics 13 397 409 1:STN:280:DyaK1c3jvVKhsQ%3D%3D 10.2165/00019053-199813040-00003 10178664 (Pubitemid 28140699)
34. J.M. Rodriguez Barrios 2004 Papel de los modelos en las evaluaciones económicas en el campo sanitario Farm Hosp 28 231 242 1:STN:280:DC%2BD2cvptFCjug%3D%3D 15369433
35. Drummond MF, Sculpher MJ, Torrance BJ et al (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press
36. X.H. Zhou C.A. Melfi S.L. Hui 1997 Methods for comparison of cost data Ann Intern Med 127 752 756 1:STN:280:DyaK2svmvVKitA%3D%3D 9382393
37. Briggs A, Goeree R, Blackhouse G, O'Brien B (2001) Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastro-esophageal reflux disease. McMaster University Centre for Heatlh Economics and Policy Analysis Research Working Paper 01-01
38. A. Briggs 2005 Probabilistic analysis of costeffectiveness models: statistical representation of parameter uncertainty Value Health 8 1 2 10.1111/j.1524-4733.2005.08101.x 15841888 (Pubitemid 40293635)
39. J.A. Sacristán J. Oliva J. Del Llano L. Prieto J.L. Pinto 2002 ¿Qué es una tecnología sanitaria eficiente en España? Gac San 16 334 343
40. J. Hutton R. Brown M. Borowitz, et al. 1996 A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer Pharmacoeconomics 9 8 22 10.2165/00019053-199600092-00004 10163967
41. R. Launois J. Reboul-Marty B. Henry J. Bonneterre 1996 A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine Pharmacoeconomics 10 504 521 1:STN:280:DyaK2s7jt1ygug%3D%3D 10.2165/00019053-199610050-00008 10169397
42. G.C. Yee 1997 Cost-utility analysis of taxane therapy Am J Health-Syst Pharm 54 Suppl2 S11 S15 1:STN:280:DyaK1c%2FpvVamsg%3D%3D 9435927
43. H.M. Lamb L.R. Wiseman 1998 Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer Pharmacoeconomics 14 447 459 1:STN:280:DyaK1M7js1Kruw%3D%3D 10.2165/00019053-199814040-00010 10344911 (Pubitemid 28455691)
44. R.E. Brown J. Hutton 1998 Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients Anti-Cancer Drugs 9 899 907 1:CAS:528:DyaK1MXhtVSitr0%3D 10.1097/00001813-199811000-00009 9890701
45. M. Martin-Jimenez A. Rodriguez-Lescure M. Ruiz-Borrego 2009 Cost effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer Clin Transl Oncol 11 41 47 1:STN:280:DC%2BD1M%2Fot1Omtg%3D%3D 10.1007/s12094-009-0309-y 19155203
46. L.P. Garrison Jr P.J. Neumann P. Erickson, et al. 2007 Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report Value Health 10 326 335 10.1111/j.1524-4733.2007.00186.x 17888097 (Pubitemid 47481104)